Abbott Laboratories Corporation

Abbvie Inc.

Robert G Schmidt

Arthur Gomtsyan

Erol K Bayburt

Chih-hung Lee

Jerome F Daanen

John R Koenig

Michael E Kort

Richard J Perner

Stanley DiDomenico

Philip R Kym

Sean Colm Turner

Guo Zhu Zheng

Tammie K White

Brian S Brown

Eric A Voight

Irene I Drizin

Steven P Latshaw

Phil B Cox

Michael J Dart

Tammie K Jinkerson

Kirill A Lukin

Russell Drew Cink

Gilles Chambournier

Margaret Chi-Ping Hsu

Bruce Clapham

Anil Vasudevan

Gregory A Gfesser

Marvin Robert Leanna

Jun Chen

Heath A McDonald

Stevan Wakefield Djuric

Clara I Villamil

Kristine E Frank

Kevin R Woller

Kenton L Longenecker

Michael M Friedman

Kennan C Marsh

Mark A Matulenko

Ryan G Keddy

Justin D Dietrich

Eric C Breinlinger

Noel S Wilson

Augustine Osuma

Robert M Leanna

Weili Wang

Ann Marie Rowley

Huan-Qui Li

Amanda W Dombrowski

Arthur R Gomtsyan

Chih-Hung Lee

Margaret Hsu

Russel D Cink

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

Tricyclic modulators of TNF signaling

Disclosed herein are modulators of TRPV3 of formula (I) wherein X, X, R, R, R, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

TRPV3 modulators

Disclosed herein are modulators of TRPV3 of formula (II): wherein G, X, X, X, X, X, G, R, R, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G, X, X, X, X, X, G, Z, R, R, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X-X, R-R, Z-Zand Arare defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds that are antagonists of the VR1 receptor, having formula (I) or a pharmaceutically acceptable salt, prodrug, or salt of a prodrug thereof, wherein A, A, A, A, R, R, R, X, Y, Z, L, n, and m, are as defined herein, and are useful in disorders prevented or ameliorated by inhibiting the VR1 receptor.

Tetrahydroquinolinyl compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

The present application is directed to compounds that are TRPV1 antagonists and have formula (I) wherein variables Ar, L, R, R, R, R, R, Y, Y, and Y, are as defined in the description, which are useful for treating disorders caused by or exacerbated by vanilloid receptor activity.

Antagonists of the TRPV1 receptor and uses thereof

The present invention relates to compounds of formula (I) wherein X, R, R, R, R, R, m, and n are defined in the specification are TRPV1 antagonists. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X, X, X, X, X, R, R, R, R, R, R, Z, Zand L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) wherein A, R, R, and Rare defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.

Prodrugs of compounds that inhibit TRPV1 receptor

The present invention discloses novel compounds of general formula (I) 

Growing community of inventors

Waukegan, IL, United States of America

Robert G Schmidt